These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 24322529

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C, Bijelic L, Sugarbaker PH.
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [Abstract] [Full Text] [Related]

  • 4. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V, Sleightholm RL, Rusthoven CG, Koshy M, Sher DJ, Grover S, Simone CB.
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [Abstract] [Full Text] [Related]

  • 5. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M.
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [Abstract] [Full Text] [Related]

  • 6. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M, RENAPE Network.
    Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
    [Abstract] [Full Text] [Related]

  • 7. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H.
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [Abstract] [Full Text] [Related]

  • 8. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA, RENAPE Working Group.
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [Abstract] [Full Text] [Related]

  • 9. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S.
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [Abstract] [Full Text] [Related]

  • 10. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.
    Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2014 May; 21(5):1448-55. PubMed ID: 24197761
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N, Sardi A, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V.
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [Abstract] [Full Text] [Related]

  • 12. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F.
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [Abstract] [Full Text] [Related]

  • 13. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms.
    Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2016 Feb; 23(2):382-90. PubMed ID: 26429720
    [Abstract] [Full Text] [Related]

  • 14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
    Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM.
    Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
    [Abstract] [Full Text] [Related]

  • 15. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y, Alzahrani NA, Liauw W, Morris DL.
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [Abstract] [Full Text] [Related]

  • 16. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S.
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y, Li XB, Lin YL, Ma R, Ji ZH, Zhang YB, An SL, Liu G, Yang XJ, Li Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar 25; 24(3):230-239. PubMed ID: 34645167
    [Abstract] [Full Text] [Related]

  • 18. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.
    Ann Surg Oncol; 2009 Feb 25; 16(2):463-72. PubMed ID: 19082859
    [Abstract] [Full Text] [Related]

  • 19. A novel nomogram for peritoneal mesothelioma predicts survival.
    Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
    Ann Surg Oncol; 2013 Feb 25; 20(2):555-61. PubMed ID: 23233234
    [Abstract] [Full Text] [Related]

  • 20. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
    Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim L, Malka D, Ducreux M, Elias D, Goéré D.
    Ann Surg Oncol; 2017 Nov 25; 24(12):3640-3646. PubMed ID: 28849389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.